View Older Stories View More Recent Stories

Mar 23, 2023 07:00AM Exscientia Business and Financial Update for the Full Year 2022
Mar 16, 2023 07:00AM Exscientia to Report Full Year 2022 Financial Results on March 23, 2023
Mar 15, 2023 07:00AM Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR
Mar 14, 2023 07:00AM Exscientia Announces Expansion of its Precision Oncology Pipeline
Mar 9, 2023 09:00AM Moelis & Company Appoints Elizabeth Crain to Vice Chair and Kate Pilcher Ciafone to Chief Operating Officer
Mar 7, 2023 07:00AM Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform
Feb 23, 2023 07:00AM EQRx Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Progress
Feb 22, 2023 08:00AM Exscientia to Present at Upcoming Investor Conferences in March
Feb 2, 2023 08:00AM Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
Dec 6, 2022 07:00AM Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress
Nov 28, 2022 07:01AM Exscientia plc (EXAI) Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
Nov 28, 2022 07:00AM Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
Nov 15, 2022 08:00AM Exscientia Business and Financial Update for the Third Quarter 2022
Nov 14, 2022 07:00AM Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments
Nov 10, 2022 07:00AM EQRx Provides Portfolio and U.S. Commercial Strategy Updates; Reports Third Quarter 2022 Financial Results
Nov 8, 2022 07:00AM Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022
Nov 3, 2022 07:00AM Exscientia Expands Biologics Design Capability with Automated Laboratory
Nov 1, 2022 08:00AM Exscientia to Present at Upcoming Investor Conferences in November
Oct 28, 2022 09:05AM Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award
Oct 28, 2022 09:00AM The Galien Foundation Honors 2022 Prix Galien Award Recipients
Oct 26, 2022 08:00AM Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium
Sep 28, 2022 08:55AM Optimize Claims Processing with expert.ai’s New Guidewire Marketplace App
Sep 20, 2022 09:00AM Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes
Sep 8, 2022 08:00AM Exscientia Welcomes Caroline Rowland as Chief People Officer
Sep 7, 2022 08:00AM Exscientia to Present at Upcoming Investor Conferences in September
Aug 17, 2022 04:01PM Exscientia Business Update for Second Quarter and First Half 2022
Aug 10, 2022 08:00AM Exscientia to Report Second Quarter 2022 Financial Results on August 17, 2022
Jul 28, 2022 09:00AM The Galien Foundation Announces 2022 Prix Galien USA Nominees for "Best Digital Health Solution," "Incubators, Accelerators and Equity," and "Prix Galien Startup"
Jun 14, 2022 08:04AM Exscientia plc (EXAI) Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers
Jun 14, 2022 08:00AM Exscientia Reports Topline Data From EXS-21546 Phase 1a Study Demonstrating Targeted A2A Receptor Signaling Inhibition in Healthy Volunteers
Jun 7, 2022 08:30AM Exscientia to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
May 25, 2022 04:01PM Exscientia plc (EXAI) Provides Q1 Business Update
May 25, 2022 04:01PM Exscientia Business Update for First Quarter 2022
May 18, 2022 08:00AM Exscientia to Report First Quarter 2022 Financial Results on May 25, 2022
May 3, 2022 04:30PM Exscientia to Present at the BofA Securities 2022 Healthcare Conference
Apr 8, 2022 04:01PM Exscientia plc (EXAI) Presents Three Posters Demonstrating Potential of Precision Medicine Platform in Drug Discovery
Apr 8, 2022 04:01PM Exscientia Presents Three Posters Demonstrating Potential of Precision Medicine Platform in Drug Discovery at the American Association of Cancer Research Annual Meeting 2022
Apr 5, 2022 08:00AM Michael Krams, M.D., Joins Exscientia as Chief Quantitative Medicine Officer
Mar 23, 2022 04:01PM Exscientia Business Update for Fourth Quarter and Full Year 2021
Mar 23, 2022 07:00AM EQRx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Progress
Mar 16, 2022 08:00AM Exscientia to Report Fourth Quarter and Year End 2021 Financial Results on March 23, 2022
Mar 10, 2022 08:00AM Exscientia and University of Oxford Launch “Xcellomics” Program to Expedite Early-Stage Academic Research and Translate Novel Biology Into Future Drug Discovery
Mar 8, 2022 04:30PM Exscientia to Highlight Precision Medicine Platform and Pipeline Data at the American Association of Cancer Research Annual Meeting 2022
Feb 22, 2022 08:00AM Exscientia to Present at Upcoming Investor Conferences in March
Jan 27, 2022 08:30AM Expert.ai Strengthens Business Agreement with Multinational Insurance Company RSA
Jan 19, 2022 06:01AM Exscientia plc (EXAI) Appoints Charlotte Deane as Chief Scientist of Biologics AI
Jan 19, 2022 06:00AM Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AI
Jan 7, 2022 06:02AM Exscientia plc (EXAI) and Sanofi (SNY) Announce Strategic Collaboration to Develop AI-Drive Pipeline of Precision-Engineered Medicines
Jan 7, 2022 01:00AM Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
Jan 7, 2022 01:00AM Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines
View More Recent Stories View Older Stories